Q32 Bio Inc. — Director's Dealing 2018

Dec 18, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-12-14

Reporting Person: TZIANABOS ARTHUR (Director, President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-12-14	Employee stock option	$24.28	A	203000	Acquired	2028-12-14	Common Stock (203000)	Direct

Footnotes

F1: The option vests in 48 equal monthly installments on the first day of each calendar month following January 1, 2019.